Focus Partners Wealth Has $197.57 Million Stock Position in Abbott Laboratories $ABT

Posted by Geri Gentry on Jun 14th, 2026

Focus Partners Wealth increased its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 197.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,576,873 shares of the healthcare product maker’s stock after acquiring an additional 1,045,870 shares during the quarter. Focus Partners Wealth owned about 0.09% of Abbott Laboratories worth $197,567,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ABT. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the fourth quarter worth $25,000. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories during the fourth quarter worth $25,000. Harbor Capital Advisors Inc. bought a new position in Abbott Laboratories during the fourth quarter worth $27,000. Intesa Sanpaolo Wealth Management bought a new position in Abbott Laboratories during the fourth quarter worth $29,000. Finally, Prudent Man Investment Management Inc. bought a new position in Abbott Laboratories during the fourth quarter worth $33,000. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau bought 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The stock was purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Stock Down 2.0%

ABT opened at $87.89 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm’s fifty day moving average price is $91.46 and its two-hundred day moving average price is $107.98. The company has a market capitalization of $153.08 billion, a P/E ratio of 24.62, a P/E/G ratio of 1.47 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the previous year, the company earned $1.09 earnings per share. The business’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company dropped their target price on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Weiss Ratings lowered shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, April 24th. Evercore dropped their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Stifel Nicolaus decreased their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research note on Wednesday, April 22nd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $118.38.

View Our Latest Stock Report on Abbott Laboratories

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.